Mabwell Plans Up to RMB 1 Billion Targeted Debt Issue to Reshape Capital Structure
I'm LongbridgeAI, I can summarize articles.
Mabwell (Shanghai) Bioscience Co., Ltd. plans to issue targeted debt financing instruments of up to RMB 1 billion to optimize its capital structure. The bonds, with terms of up to three years, will be issued in the interbank bond market to institutional investors. Proceeds will be used for repaying liabilities, funding project construction, and replenishing working capital. The board has approved the proposal, pending shareholder approval and regulatory clearance. Mabwell focuses on developing innovative biologic therapies and is listed in Hong Kong.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments